Roxana-Elena Cîrjaliu

Dr. Roxana-Elena Cîrjaliu

pneumology, Ovidius University, Constanţa, Romania
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
RCRoxana-Elena Cîrjaliu
Roxana-Elena Cîrjaliu
MDMariana Deacu
Mariana Deacu
IGIoana Gherghișan
Ioana Gherghișan
MȘMarghescu Angela Ștefania
Marghescu Angela Ștefania
MEManuela Enciu
Manuela Enciu
AFARIADNA PETRONELA FILDAN
ARIADNA PETRONELA FILDAN
This review brings together the current knowledge regarding the risk factors and the clinical, radiologic, and histological features of both post-COVID-19 pulmonary fibrosis (PCPF) and idiopathic pulmonary fibrosis (IPF), describing the similarities and the disparities between these two diseases, using numerous databases to identify relevant articles published in English through October 2022. This review would help clinicians, pathologists, and researchers make an accurate diagnosis, which can help identify the group of patients selected for anti-fibrotic therapies and future therapeutic perspectives.

10 July 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
RCRoxana-Elena Cîrjaliu
Roxana-Elena Cîrjaliu
ITIoan-Tiberiu Tofolean
Ioan-Tiberiu Tofolean
DTDoina-Ecaterina Tofolean
Doina-Ecaterina Tofolean
ACAnca Chisoi
Anca Chisoi
Cristian OanceaCristian Oancea
Cristian Oancea
AFARIADNA PETRONELA FILDAN
ARIADNA PETRONELA FILDAN
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates advanced prognostic tools to anticipate disease progression and optimize patient outcomes. This study evaluates the predictive value and diagnostic potential of interleukins interleukin (IL) IL-10, IL-17A, IL1-β, IL-6, chemokine ligand (CXCL), and Monocyte Chemotactic Protein (MCP) for severe coronavirus disease 2019 (COVID-19) and COVID-19 mortality, aiming to correlate cytokine levels with disease severity. Conducted from January 2023 to January 2024, this prospective cohort study involved patients hospitalized with moderate and severe COVID-19 from Romania. This study analyzed statistically significant predictors of severe COVID-19 outcomes. IL-6 and MCP emerged as significant, with hazard ratios (HRs) of 2.35 (95% confidence interval (CI): 1.54–3.59, p = 0.014) and 2.05 (95% CI: 1.22–3.45, p = 0.007), respectively. Compound scores integrating multiple inflammatory markers also demonstrated predictive value; Compound Score 2 had an HR of 2.23 (95% CI: 1.35–3.68, p = 0.002), surpassing most single markers in association with severe disease. Notably, interleukins IL-10 and IL-1β did not show significant associations with disease severity. This study underscores the importance of IL-6 and MCP as robust predictors of severe COVID-19, substantiating their role in clinical assessments to foresee patient deterioration. The utility of compound scores in enhancing predictive accuracy suggests a composite approach may be more effective in clinical settings.

4 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
RCRoxana-Elena Cîrjaliu
Roxana-Elena Cîrjaliu
MDMariana Deacu
Mariana Deacu
IGIoana Gherghișan
Ioana Gherghișan
MȘMarghescu Angela Ștefania
Marghescu Angela Ștefania
MEManuela Enciu
Manuela Enciu
AFARIADNA PETRONELA FILDAN
ARIADNA PETRONELA FILDAN
This review brings together the current knowledge regarding the risk factors, and the clinical, radiologic and histological features of both post-COVID-19 interstitial pul-monary fibrosis (PCPF) and Idiopathic Pulmonary Fibrosis (IPF) with a particular fo-cus on describing the similarities and the disparities between the fibrotic changes in these two diseases. It is important to highlight the common points of PCPF and IPF to observe if they are some targetable changes to improve patient outcomes. The litera-ture review was performed using numerous databases to identify relevant articles published in English through October 2022. This review would help clinicians, pathologists and researchers to make an accurate diagnosis, which can be useful in identifying the group of patients who can be selected for antifibrotic therapies, and future therapeutic perspectives.

8 November 2024 in Diseases
Verified
Journal Article
Open access
PDF file
RCRoxana-Elena Cîrjaliu
Roxana-Elena Cîrjaliu
SGSri Vidhya Gurrala
Sri Vidhya Gurrala
BNBalaji Nallapati
Balaji Nallapati
VKVamsi Krishna
Vamsi Krishna
Cristian OanceaCristian Oancea
Cristian Oancea
AFARIADNA PETRONELA FILDAN
ARIADNA PETRONELA FILDAN
Pulmonary fibrosis detected during the acute phase of SARS-CoV-2 infection may significantly influence patient prognosis. This study aimed to evaluate the prognostic value of initial high-resolution computed tomography (HRCT) findings of pulmonary fibrosis in hospitalized COVID-19 patients and to examine how these findings relate to disease severity and clinical outcomes, with a particular focus on the development and validation of predictive scoring systems. In this multicentric prospective cohort study from January 2023 to January 2024, 120 adult patients with confirmed SARS-CoV-2 infection requiring hospitalization were enrolled from two Romanian university hospitals. Patients were categorized based on the presence (n = 60) or absence (n = 60) of pulmonary fibrosis signs on admission HRCT scans, identified by reticular opacities, traction bronchiectasis, honeycombing, and architectural distortion. Biochemical analyses, severity scores (SOFA, APACHE II, NEWS 2), and novel compound scores combining clinical and radiological data were assessed. Patients with HRCT evidence of pulmonary fibrosis had significantly higher severity scores and worse clinical outcomes. The HRCT score alone was a strong predictor of severe COVID-19 (area under the ROC curve [AUC] = 0.885), with a best cutoff value of 9.72, yielding 85.7% sensitivity and 79.8% specificity. Compound Score 1, integrating SOFA, APACHE II, and HRCT scores, demonstrated excellent predictive performance with an AUC of 0.947, sensitivity of 92.5%, and specificity of 88.9%. Compound Score 2, combining systemic inflammation markers (SIRI, SII) and NEWS 2, also showed a strong predictive capability (AUC = 0.913), with 89.2% sensitivity and 85.7% specificity at the optimal cutoff. Regression analysis revealed that Compound Score 1 had the highest hazard ratio for severe COVID-19 outcomes (HR = 4.89; 95% CI: 3.40–7.05), indicating its superior prognostic value over individual markers and traditional severity scores. Initial HRCT findings of pulmonary fibrosis are significantly associated with increased disease severity in hospitalized COVID-19 patients. The HRCT score is a valuable prognostic tool, and, when combined with clinical severity scores into Compound Score 1, it enhances the prediction of severe COVID-19 outcomes with high sensitivity and specificity. These compound scores facilitate the early identification of high-risk patients, guiding clinical decision-making and optimizing patient management to improve outcomes.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
RCRoxana-Elena Cîrjaliu
Roxana-Elena Cîrjaliu
DTDoina-Ecaterina Tofolean
Doina-Ecaterina Tofolean
EDElena Dantes
Elena Dantes
OAOana Cristina Arghir
Oana Cristina Arghir
LHLaurențiu-Tony Hangan
Laurențiu-Tony Hangan
AFAriadna-Petronela Fildan
Ariadna-Petronela Fildan
Introduction: Post COVID-19 (Coronavirus disease2019) pulmonary fibrosis (PCPF) is a common Covid-19 sequela, the risk factors, treatment and prognosis being unknown, needing further studies for investigation. Aims and objectives: This study aims to evaluate the risk factors for developing PCPF. Methods: We conducted a retrospective study on a group of 85 patients admitted in the Pneumology Hospital of Constanta on the year 2022. The patients were hospitalized for COVID-19 and later were evaluated at 3 months after the acute episode. The collected data included socio-demographic aspects, comorbidities, clinical status, biologic, and imagistic investigations. Results: From the patients analyzed, 34 (40%) develop PCPF visible on the CT (computer tomography) scan performed at 3 months after the acute episode. The average age was 72 years, 17 patients (50%) having being between 70 to 79 years old. The male gender was dominant. The most common comorbidities were arterial hypertension (41.17%), diabetes (26.47%), COPD (23.52%). Regarding the COVID-19 severity, 26 patients (76.47%) had severe form of the disease at the initial CT investigation, the others having moderate form. During the hospitalization for the acute episode 88.23 % patients who later developed PCPF required oxygen therapy. Other common risk factors found were smoking in 61.76% and alcohol consumption in 38.25% of cases. 82.35% had persistent inflammatory syndrome, with increased fibrinogen, C reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Conclusions: COVID-19 can cause PCPF, the risk factors that can rise an alarm signal being male gender, increased age, smoking, severe form of COVID-19, persistent inflammatory syndrome.